Neuralink PRIME Study: Status, Design, and Results

Neuralink PRIME Study Research Profile

PRIME is Neuralink's first-in-human early feasibility study of the N1 Implant and R1 Robot for control of external devices. The current ClinicalTrials.gov record lists the study as recruiting and shows no posted results.

That is the answer-first evidence state. Sponsor updates describe individual experiences and technical observations, but they are not a substitute for completed registry results or independent clinical analysis.

flowchart TD
    A["Registry facts"] --> E["Current evidence state"]
    B["FDA guidance"] --> E
    C["Sponsor updates"] --> E
    D["Participant reports"] --> E
    E --> F["Qualified clinical review"]
    F --> G["Future result or decision"]

Study record

The current ClinicalTrials.gov record was checked on July 28, 2026. The site identifies January 9, 2026 as the last posted update. Status, dates, enrollment, locations, outcomes, and results can change.

What PRIME is asking

The registry describes a first-in-human study evaluating initial clinical safety and device functionality in participants with tetraparesis or tetraplegia. The devices are the N1 Implant and R1 Robot. The intended task concerns external-device control.

That question is narrower than many public discussions of Neuralink. PRIME does not establish that N1 restores walking, treats every cause of paralysis, is suitable for any particular person, or is ready for routine clinical use.

An early feasibility study exists to learn under controlled conditions while important uncertainty remains. Its design should not be narrated as a commercial release.

What the regulatory pathway means

Neuralink's recruitment announcement states that PRIME proceeds under an FDA investigational device exemption.

The FDA's IDE overview explains that an IDE permits an investigational device to be used in a clinical study to collect safety and effectiveness data. Covered research is subject to applicable institutional review, informed consent, monitoring, labeling, records, and reports.

An IDE is not marketing approval. It does not establish completed evidence of safety or effectiveness.

The FDA's implanted BCI guidance provides recommendations for nonclinical testing and clinical study considerations. It is general guidance for the field. It does not determine the outcome of PRIME.

What Neuralink reported about the first participant

Neuralink's May 2024 update names Noland Arbaugh and describes computer control, games, web use, and extended device use. Arbaugh described greater independence and comfort compared with the setup he had previously used.

The same update reports thread retraction and a related decline in effective electrodes and measured cursor performance. Neuralink says it changed recording sensitivity, translation techniques, and the user interface, after which measured performance improved.

That is a meaningful sponsor disclosure. It does not tell the reader the full clinical significance, long-term device state, or outcome across the study.

Neuralink states that benefit from PRIME participation is not guaranteed.

Later sponsor reports

Neuralink's August 2024 second-participant update describes computer use, design software, games, and the company's thread-retraction mitigation claims for another participant.

Neuralink has since announced additional participants and studies. Its current device-control page links N1 research to PRIME and CONVOY. Those developments show that the sponsor's program has expanded.

They do not change the evidence class of the PRIME registry. A participant count across programs is not PRIME enrollment data. A new study does not supply PRIME results. A sponsor story does not become an independent finding because more time has passed.

How to interpret no posted results

"No results posted" is a registry state. It does not mean the intervention worked, failed, or produced no observations. It means the public record does not contain a posted results section for this study.

The estimated primary-completion date of June 2026 should also be read carefully. Estimated dates can change. Reaching a date does not prove that follow-up, analysis, quality checks, or reporting are complete.

A publication-ready update should inspect the registry history, current status, posted results, peer-reviewed publications, regulator communications, and sponsor disclosures. Each source should retain its date and evidence class.

Questions a future result should answer

A complete evaluation would examine participant disposition, device and procedure events, outcome definitions, follow-up, missing data, protocol changes, technical performance, functional use, quality-of-life measures, variation across participants, and uncertainty.

It would also distinguish the implanted device, surgical process, decoding software, support model, and external device. A favorable result for one component should not silently validate the entire system.

Venture Step context

E010 was recorded soon after Arbaugh's first public demonstration. The episode captured the practical importance of direct computer control but used approval language too broadly. The corrected package describes N1 as investigational and Arbaugh's account as one participant's sponsor-reported experience.

Read [[Neuralink N1 Implant Product Profile]] for the device record and [[Neuralink Company Profile]] for sponsor identity. [[How to Evaluate a High-Impact Technology Demonstration]] provides the reusable evidence ladder.

This research profile was developed with AI assistance from the preserved E010 transcript and the linked ClinicalTrials.gov, FDA, and Neuralink records. It is not medical advice, trial-recruitment advice, statistical analysis, or an assessment of whether any person should participate. Clinical, regulatory, statistical, device, safety, accessibility, and ethics review remain required. Publication is unauthorized.